agitg trial news

AGITG Trial News

AGITG Trial news: The AGITG currently has nineteen studies open to recruitment and three studies in follow up.

The table below details the AGITG trials that are currently accruing patients.

Recruited Target Recruitment Period (months) Date of First Site Open (ANZ) Number of Sites Open 
ACTICCA-1 (Cholangiocarcinoma) 29 40 72 25 July 2016 13
ASCOLT (Colorectal cancer) 466 460 48 18 June 2014 32
ASCOLT – Global 1569 1587
DYNAMIC-III (Colon cancer) 501 1000 54 09 October 2017 41
DYNAMIC-Pancreas (Pancreatic cancer) 67 438 54 01 March 2019 26
DYNAMIC-Rectal (Rectal cancer) 202 408 36 18 June 2018 37
FORECAST-1 (Colorectal cancer) 26 30 12 11 September 2020 4
GENESCREEN 5-FU (Pan Tumour) 11 50 50 1 February 2021 2
INTEGRATE II (Gastro-oesophageal cancer) 77 90 48 19 October 2016 27
INTEGRATE II – Global 229 350 64
LICPIC (Colorectal cancer) 39 100 110 11 September 2018 2
MASTERPLAN (Pancreatic cancer) 12 120 48 01 October 2019 9
MONARCC (Colorectal cancer) 32 80 24 20 June 2018 21
NABNEC (Neuroendocrine tumours) 49 58 54 15 September 2016 18
OXTOX (Colorectal cancer) 2 100 18 18 December 2020 3
PALEO (Oesophageal cancer) 5 54 36 16 September 2019 1
RANDOMS (Pancreatic cancer) 2 60 48 14 December 2020 3
RENO (Rectal cancer) 32 250 36 21 January 2019 7
SPAR (Rectal cancer) 76 222 48 13 April 2018 15
TOP GEAR (Gastric & gastro-oesophageal cancer) 242 280 118 29 September 2009 27
TOP GEAR – Global 565 570 41

Recruitment figures are for Australian and New Zealand sites as at end March 2021.

Trial Results Lay Summaries (click on the links below): 
ABC
Adjuvant GIST/ EORTC 62024
AG0001H
ATTAX
ATTAX 2
Advanced GIST
AG9601
A La CaRT
ATTACHE
ATTAX-3
CO.17
CO.20
CO.23
DECO
ESPAC-3
GAP
ICECREAM
INTEGRATE
MAX
NSABP CO6
NSABP CO-7
PAN 1
REGISTER
SCOT
TACTIC
TOP GEAR
TROG 01.04 / IG0103R

Share